South Korea-based Celltrion Group has reported positive top-line results from the Phase III clinical trial of its monoclonal antibody candidate, regdanvimab (CT-P59), to treat mild-to-moderate Covid-19 symptoms.

The drug candidate met all primary and key secondary goals during the study.

Regdanvimab met the primary efficacy endpoint of a significant decrease in the risk of hospitalisation or death. It reduced the risk by 72% in patients who were at high risk of disease progression up to day 28 versus placebo.

The candidate also met the first key secondary goal with a significant reduction in the risk of hospitalisation or death by 70% in all patients.

Other key secondary endpoints, which include quicker and sustained lowering of symptom duration, were also met.

Compared to participants who received a placebo, those treated with 40mg/kg regdanvimab experienced recovery a minimum of 4.7 days earlier.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The medium recovery was 9.3 days in the treatment arm, compared to a minimum of 14 days in the placebo arm. This data was obtained from subjects at high risk of advancing to severe Covid-19.

In all subjects treated with the drug candidate, the recovery was 4.9 days earlier, with a median of 8.4 days versus 13.3 days on placebo.

According to the top-line data, regdanvimab demonstrated a positive safety profile, without any clinically meaningful differences between participants who received the treatment and those on placebo.

The company noted that infusion-related reactions were mild and transient, and the majority of patients recovered in one to three days.

Celltrion Healthcare Medical and Marketing division head Dr HoUng Kim said: “As many hospitals across the globe now exceed their ability to accommodate patients due to Covid-19, it is critical that we use every resource to reduce the burden on the healthcare system.

“This well-controlled trial provides conclusive results demonstrating that CT-P59 can improve outcomes in people with mild- to-moderate COVID-19 and also significantly reduce the risk of hospitalisation and death.”

Findings from in vivo ferret challenge studies showed that a therapeutic dosage of the drug candidate reduced the viral load of the B.1.351 SARS-CoV-2 variant in the upper and lower respiratory tracts.

This is similar to the findings for the wild-type virus. B.1.351 was first identified in South Africa.

Last month, Celltrion reported regdanvimab’s neutralising potency against SARS-CoV-2 variants first detected in New York, US (B.1.526), Nigeria (B.1.525), and India (B.1.617).